Alpha Cognition Inc., a biopharmaceutical company specializing in therapies for neurodegenerative disorders, announced that their partner, China Medical System Holdings Limited $(CMS)$, has received acceptance for their New Drug Application (NDA) by the National Medical Products Administration of China (NMPA). This NDA pertains to ZUNVEYL® (Benzgalantamine), a treatment aimed at mild-to-moderate Alzheimer's dementia. This milestone signifies a critical step toward potentially introducing this innovative therapy to the Asian market. Alpha Cognition is set to benefit from CMS's regulatory and commercial expertise in China and will receive financial gains such as regulatory and sales milestones, and royalties upon ZUNVEYL's approval for marketing in China and other Asian territories.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。